曲妥珠单抗联合TP化疗对乳腺癌术后影响-现代医学

曲妥珠单抗联合TP化疗对乳腺癌术后影响

单位：四川省人民医院乳腺科, 四川成都 610000

分类号：R737.9

出版年·卷·期（页码）：2018·46·第五期（537-540）

摘要：

目的：探讨曲妥珠单抗联合TP化疗对乳腺癌术后影响。方法：选取2014年1月至2016年1月收治的100例乳腺癌患者，按随机数字表法分为对照组和观察组，各50例。术前对照组采用单一TP化疗方案，观察组实施曲妥珠单抗联合TP治疗方案。对比两组患者的疗效、生存质量及不良反应发生率，并对比患者血清因子水平的变化。结果：观察组总有效率为86%（43/50），明显高于对照组的76%（38/50）（P<0.05）。治疗后，观察组的生活质量评分明显高于对照组，血管生成因子VEGFA、VEGFB及VEGFC明显低于对照组（P<0.05）。术后3、6个月，两组患者的不良反应发生率差异无统计学意义（P>0.05）。结论：术前采用曲妥珠单抗联合TP化疗治疗乳腺癌，能改善患者的生活质量，提高患者的短期治疗效果。

Objective: To explore the effect of trastuzumab combined with TP chemotherapy on postoperative breast cancer.Methods: 100 cases of breast cancer patients were randomly selected in our hospital from January 2014 to January 2016, and randomly divided intocontrol group and observation group, 50 cases in each group. The control group was treated with a single TP chemotherapy regimen, and the observation group was treated with trastuzumab combined with TP chemotherapy. The curative effect, quality of life and incidence of adverse reactions were compared between the two groups after treatment, and the changes of serum factors were compared.Results: The total effective rate of the observation group was 86% (43/50), which was significantly higher than that of the control group (38/50,P<0.05). After treatment, the quality of life score of the observation group was significantly higher than that of the control group, and the angiogenic factors VEGFA, VEGFB and VEGFC were significantly lower than those of the control group (P<0.05). After 3 and 6 months, there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion: Preoperative use of trastuzumab combined with TP chemotherapy in the treatment of breast cancer can improve the quality of life of the patients and improve the short-term therapeutic effect of the patients.

参考文献：

[1] 田传兴,李同霞.中西结合治疗对乳腺癌治疗效果、生活质量及预后的评价研究[J].中华中医药学刊,2016,34(9):2283-2285.
[2] 俞春燕,蔡鑫君,倪坚军,等.节拍式化疗用于晚期卵巢癌的临床研究进展[J].中国现代应用药学,2016,33(11):1487-1492.
[3] MARQUES S,FONSECA J,SILVA P M,et al.Targeting the spindle assembly checkpoint for breast cancer treatment[J].Curr Cancer Drug Targets,2015,15(4):272-281.
[4] 孙愚,李帅,罗婷,等.曲妥珠单抗联合新辅助化疗对HER-2阳性乳腺癌患者近远期疗效的影响[J].实用癌症杂志,2016,31(8):1355-1356.
[5] 魏杰,王志国,朱诚,等.荧光染料偶联抗HER-2单链抗体对乳腺癌的体内外检测研究[J].标记免疫分析与临床,2017,24(6):647-650.
[6] SUN Q,LIU T,YUAN Y,et al.MiR-200c inhibits autophagy and enhances radiosensitivity in breast cancer cells by targeting UBQLN1[J].Int J Cancer,2015,136(5):1003-1012.
[7] 吴延春,许新堂.联合钼靶X线摄影、MRI动态增强及弥散加权成像对乳腺癌的诊断价值[J].现代医学,2016,44(10):1327-1332.
[8] 韩樱松,孙桂彬,冯瑾.放化疗联合生物靶向治疗对乳腺癌早期改良根治术后患者远期生存率的影响[J].实用癌症杂志,2017,32(9):1460-1463.
[9] 龙景培,万芳,周俊,等.MiR-182对乳腺癌细胞顺铂耐药的相关性研究[J].中国现代应用药学,2016,33(6):721-726.
[10] 魏微,闫泽强.曲妥珠单抗联合IP化疗方案治疗HER-2阳性晚期胃癌的疗效观察[J].现代药物与临床,2017,32(3):505-508.
[11] ANDRÉ F,CORTÉS J.Rationale for targeting fibroblast growth factor receptor signaling in breast cancer[J].Breast Cancer Res Treat,2015,150(1):1-8.
[12] 王峰,李梅,朱建伟,等.SIRT3在乳腺癌中的表达与临床预后的相关性分析[J].东南大学学报(医学版),2017,36(4):524-529.
[13] LI J T,JIA LT,LIU N N,et al.MiRNA-101 inhibits breast cancer growth and metastasis by targeting CX chemokine receptor 7[J].Oncotarget,2015,6(31):30818-30830.
[14] 周永安,刘训碧.曲妥珠单抗联合多西紫杉醇治疗Her-2阳性乳腺癌的临床研究[J].现代药物与临床,2016,31(6):863-867.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录